Revvity - AAV Capsid Development

We work very closely with our clients, providing expertise, ideas, and innovation throughout the process – acting as an extension of the client’s team and always keeping their end goal in mind. We regularly report on progress to keep them well-informed, and draw on our many years of experience in AAV manufacturing and development to help deliver quality viral vectors in a timely manner. Our collaborative and consultative approach also includes identifying and managing technology partners in the form of professional alliance management.

So, if you’re looking for an experienced, collaborative and innovative partner to develop improved viral vectors, which can help to deliver therapeutic genes to the target, reduce dosages and mitigate side effects, look no further.

AAV capsid directed evolution

To optimize AAV tropism, our RNA-driven technology uses a directed evolution approach via capsid randomization. This technology is made available through the partnership and license agreements between Revvity and Heidelberg University in Germany. Under these agreements, Revvity works closely with Prof. Dr. Dirk Grimm, a pioneer in AAV capsid evolution.

AAV directed capsid evolution entails:

• Iterative in vivo screenings of recombinant AAV (rAAV) libraries harboring randomized peptide insertion libraries or AAV shuffled variants or combinations thereof.
• In vivo biodistribution analysis of enriched barcoded AAVs.
• AAV lead candidates are identified using advanced single cell-based analysis, with data collections obtained from next generation sequencing and PCR techniques from transduced tissue.

AAV rational design – nanobody targeting

Highly specific nanobodies are the basis of a novel rational design strategy that allows direct targeting of a surface protein of interest.

This technology can be implemented separately or in combination with directed evolution of AAV capsids to further enhance cell or tissue tropism and minimize off-target effects.

The success of AAV in vivo experiments is dependent on vector quality and titer. Equally important is the correct choice of serotype and expression cassette design (e.g.promoter).
When choosing our custom AAV service, SIRION Biotech’s technical experts will assist you to identify the optimal setting for your specific application and engineer AAV vectors exactly to your specification to perfectly fit your needs.

SIRION benefits

• Personal technical consultation at all stages of the project
• Strong tissue targeting with a state-of-the-art serotype and promoter portfolio
• Expert expression cassette design optimization
• Custom adjustment of upstream and downstream process steps to best fit your project needs
• Highest quality standards and upscaling options to fit any stage from discovery to late preclinical
• A constantly growing selection of premium QC options to meet regulatory requirements